Lobbying

Corporate funding of The NCD Alliance

The NCD Alliance is a formal alliance of the International Diabetes Federation, The International Union Against Tuberculosis and Lung Disease, Union for International Cancer Control and the World Heart Federation established on 19 May 2009 "representing the four main NCDs outlined in the World Health Organization’s 2008-2013 Action Plan for NCDs – cardiovascular disease, diabetes, cancer, and chronic respiratory disease".

IIPI side event at WIPO to present on a joint USPTO/IIPI project on "Missed Opportunities Patenting in Developing Countries"

The International Intellectual Property Institute (IIPI) is holding a side event at WIPO today on the margins of the WIPO Committee on Development and Intellectual Property (CDIP) on "Missed Opportunities for Patenting in Developing Countries" and "Innovation Opportunities in the Philippines".

The program flyer for the event notes that this initiative is a "joint project between the Intellectual Property Institute (IIPI) and the U.S. Patent and Trademark Office (USPTO)."

US Industry IP memo for the TPP negotiations leaked

Knowledge Ecology International (KEI) has received a copy of U.S. industry demands on the Intellectual Property chapter of the Trans-Pacific Partnership Agreement (TPP) negotiations. A draft letter from US industry to USTR has been leaked and is available here.

Ari Emanuel: Did he mention lobbying the President or the Vice President?

See update at the end. ----------

Medical professional and patient group funding by drug and medical device companies

2010

Jeffrey Kindler rewarded by Pfizer for his influence with governments

On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.

PhRMA's revolving door

The following are a few notes on PhRMA's revolving door with the federal government.

Billy Tauzin. Former member of Congress from Louisiana.

Chris Singer. Previously served as a professional staff member for the U.S. House Appropriations Committee.

Brian Toohey. Former Desk Officer and Deputy Director in the European Office of the U.S. Department of Commerce.

Billy Tauzin's 2008 compensation from PhRMA was $4,476,157

Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.

PhRMA's 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:

Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465

Total: $4,476,157

PhRMA's grants to US organizations in 2008

In the United States, tax exempt non-profit organizations are subject some some requirements for financial disclosure via the IRS form 990, which is available to the public. The disclosure requirements cover most U.S. based trade associations, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade association for some 28 "member" companies.

Syndicate content